Presented at ESTRO 2016, Turin, Italy
Y. Tao (1), C. Le Tourneau (2), H. Bouchaab (3), J. Delord (4), V. Calugaru (2), P. Crompton (5), E. Rouits (6), B. Gavillet (6), C. Zanna (5), C. Schusterbauer (5), E. Deutsch (1), J. Bourhis (3)
- Institut Gustave Roussy, Département de radiothérapie, Villejuif, France,
- Institut Curie, Département d’oncologie médicale, Paris, France,
- Département d‘oncologie UNIL-CHUV, Service de radio-oncologie, Lausanne, Switzerland,
- IUTC Oncopole, Oncologie médicale, Toulouse, France,
- Debiopharm International SA, Clinical Research & Development, Lausanne, Switzerland,
- Debiopharm International SA, Translational Medicine, Lausanne, Switzerland,
- Département d’oncologie UNIL-CHUV, Service de radio-oncologie, Lausanne, Switzerland.